UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 103 filers reported holding UROGEN PHARMA LTD in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $314,218 | +33.6% | 21,823 | 0.0% | 0.07% | +39.6% |
| Q2 2023 | $235,143 | +28.6% | 21,823 | 0.0% | 0.05% | +14.3% |
| Q1 2023 | $182,877 | -0.1% | 21,823 | 0.0% | 0.04% | -2.3% |
| Q4 2022 | $183,010 | +2.2% | 21,823 | 0.0% | 0.04% | +4.9% |
| Q3 2022 | $179,000 | +1.1% | 21,823 | 0.0% | 0.04% | +5.1% |
| Q2 2022 | $177,000 | -6.3% | 21,823 | 0.0% | 0.04% | +18.2% |
| Q1 2022 | $189,000 | -9.1% | 21,823 | 0.0% | 0.03% | -2.9% |
| Q4 2021 | $208,000 | -43.3% | 21,823 | 0.0% | 0.03% | -49.3% |
| Q3 2021 | $367,000 | +10.2% | 21,823 | 0.0% | 0.07% | +13.6% |
| Q2 2021 | $333,000 | -21.6% | 21,823 | 0.0% | 0.06% | -33.0% |
| Q1 2021 | $425,000 | +8.1% | 21,823 | 0.0% | 0.09% | +1.1% |
| Q4 2020 | $393,000 | – | 21,823 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
| Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
| Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
| MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
| DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
| SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
| BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
| Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |